Literature DB >> 22818266

Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI).

Edo Richard1, Sandrine Andrieu, Alina Solomon, Francesca Mangialasche, Satu Ahtiluoto, Eric P Moll van Charante, Nicola Coley, Laura Fratiglioni, Anna Stigsdotter Neely, Bruno Vellas, Willem A van Gool, Miia Kivipelto.   

Abstract

Recent epidemiological studies have indicated numerous associations between vascular and lifestyle related risk factors and incident dementia. However, evidence from randomised controlled trials (RCT) showing effectiveness of interventions aimed at these risk factors in preventing or postponing dementia onset is still lacking. Three large RCTs on multi-component interventions to prevent dementia (preDIVA, FINGER, MAPT) have been initiated in Europe to address these issues. Irrespective of some methodological differences, all three studies target cardiovascular and lifestyle related risk factors. Collaboration within the newly founded 'European Dementia Prevention Initiative' (EDPI) will allow for a comprehensive exploration of optimal target population, intervention and outcome measures, which are currently unknown. Combining data of the ongoing studies and running simulation analyses will facilitate determining the optimal design including accurate sample-size calculations for future multi-national clinical trials on dementia prevention. Interventions aiming at dementia prevention should be pragmatic and easy to implement on a large scale in different health care systems, without generating high additional costs or burden on participants or physicians. As the optimal age for intervention precedes the optimal age for outcome assessment, traditional trial designs might lead to suboptimal timing of either of the two. Separation of intervention and outcome assessment in time is a potential solution, but requires studies with very long follow-up. International collaboration of research groups with experience in dementia prevention studies and well-organised logistics for these major projects is pivotal to success for future large-scale dementia prevention studies. Founding of EDPI is an important first step in this direction.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22818266     DOI: 10.1016/j.jns.2012.06.012

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  39 in total

1.  Vascular Dementia.

Authors:  Alberto R Ramos; Salim I Dib; Clinton B Wright
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2013-09-01

2.  Choosing Alzheimer's disease prevention clinical trial populations.

Authors:  Joshua D Grill; Sarah E Monsell
Journal:  Neurobiol Aging       Date:  2013-10-09       Impact factor: 4.673

3.  Advances in the prevention of Alzheimer's disease and dementia.

Authors:  A Solomon; F Mangialasche; E Richard; S Andrieu; D A Bennett; M Breteler; L Fratiglioni; B Hooshmand; A S Khachaturian; L S Schneider; I Skoog; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

4.  Mid- and Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden: The Atherosclerosis Risk in Communities (ARIC)-PET Study.

Authors:  Priya Palta; Gerardo Heiss; A Richey Sharrett; Kelley Pettee Gabriel; Keenan Walker; Kelly R Evenson; David Knopman; Thomas H Mosley; Dean F Wong; Rebecca F Gottesman
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.

Authors:  Penny A Dacks; Sandrine Andrieu; Deborah Blacker; Aaron J Carman; Allan M Green; Francine Grodstein; Victor W Henderson; Bryan D James; Rachel F Lane; Joseph Lau; Pei-Jung Lin; Barnaby C Reeves; Raj C Shah; Bruno Vellas; Kristine Yaffe; Karin Yurko-Mauro; Diana W Shineman; David A Bennett; Howard M Fillit
Journal:  J Prev Alzheimers Dis       Date:  2014-02

Review 6.  Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.

Authors:  S Lista; B Dubois; H Hampel
Journal:  J Nutr Health Aging       Date:  2015-02       Impact factor: 4.075

7.  Fourth European stroke science workshop.

Authors:  S Debette; D Strbian; J M Wardlaw; H B van der Worp; Gje Rinkel; V Caso; M Dichgans
Journal:  Eur Stroke J       Date:  2018-05-24

Review 8.  Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors:  David Hsu; Gad A Marshall
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

9.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06

10.  Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults.

Authors:  Priya Palta; A Richey Sharrett; Kelley Pettee Gabriel; Rebecca F Gottesman; Aaron R Folsom; Melinda C Power; Kelly R Evenson; Clifford R Jack; David S Knopman; Thomas H Mosley; Gerardo Heiss
Journal:  Neurology       Date:  2021-01-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.